(P-617) Estimating Pediatric Breakthrough Disease from Pneumococcal Vaccines in France

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

RO

Rachel Oidtman, PhD

Associate Principal Scientist
Merck & Co., Inc.
Lansdale, Pennsylvania, United States
GM

Giulio Meleleo, PhD

Wolfram Research, Inc.
Champaign, Illinois, United States
PV

Priscilla Velentgas, PhD

Merck & Co., Inc., Rahway, NJ, USA
Philadelphia, Pennsylvania, United States
Kenneth Klinker, PharmD

Regional Medical Scientific Director
Merck & Co, Inc
Kenilworth, NJ, United States
Natalie Banniettis, MD

Director, Vaccines Clinical Research
Merck & Co., Inc.
Kenilworth, New Jersey, United States
KF

Kristen A. Feemster, MD, MPH, MSHPR, FAAP

Merck & Co., Inc.
Rahway, New Jersey, United States
JW

Jessica Weaver, PhD, MPH

Merck & Co., Inc.
Rahway, New Jersey, United States